Squarepoint Increases Holdings in Amphastar

Summary

Squarepoint Ops LLC increased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) by 208% in the fourth quarter, adding 11,929 shares for a total of 17,664 shares valued at $656,000. Other investors also increased their holdings; Tower Research Capital increased by 43.7%, Huntington National Bank by 36.9%. Analysts maintain a ‘Hold’ rating on AMPH with a consensus target price of $32.33. The stock currently trades at $25.38, down 1.3% with a market cap of $1.2 billion and a P/E ratio of 8.46.Market Beat

Impact Analysis

This event is classified at the Company Level as it specifically pertains to Amphastar Pharmaceuticals and the strategic decisions of investors in the stock. The increase in holdings by Squarepoint Ops LLC and other investors indicates confidence in Amphastar’s potential, despite the stock trading below the target price at $25.38, suggesting it might be undervalued. Analysts maintain a ‘Hold’ rating with a target price of $32.33, indicating room for growth.Market Beat This company-specific move aligns with recent analyst adjustments where JP Morgan revised Amphastar’s rating to ‘Neutral’ and decreased their target price from $45 to $30, affecting perceptions and valuation expectations.Reuters+ 2 The participation in industry conferences, like the Jefferies Global Healthcare Conference, shows proactive engagement with institutional investors, which might bolster investor confidence.Reuters Investment opportunities could include buying AMPH shares at their current lower price, anticipating potential growth. Risks include the stock’s volatility and broader market trends impacting the pharmaceutical sector.